Thursday, February 20, 2014

Characterization of biometal - profiles in neurological disorders

›
Characterization of biometal - profiles in neurological disorders . Stefanie Pfaender and Andreas M Grabrucker; Metallomics, 2014, DOI: 1...

Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features and perspectives

›
Accelerating development, registration and access to medicines for rare diseases in the European Union through adaptive approaches: features...
Sunday, February 16, 2014

Nucleoside 5’-phosphorothioate derivatives are highly effective neuroprotectants

›
Nucleoside 5’-phosphorothioate derivatives are highly effective neuroprotectants . O. Danino, N. Giladi,S. Grossman, B. Fischer; Biochemical...
Saturday, February 15, 2014

Voyager Lifts Off With $45M From Third Rock Ventures

›
Voyager Lifts Off With $45M From Third Rock Ventures . By Paul Bonanos, The pink Sheet, February 12 2014 Voyager hopes to have three progr...
Wednesday, February 12, 2014

Voyager Therapeutics, a new gene therapy company focused on CNS diseases, including Friedreich's Ataxia (FA), is launched

›
Voyager Therapeutics, a new gene therapy company focused on CNS diseases, including Friedreich's Ataxia (FA), is launched . FARA Press R...
Tuesday, February 11, 2014

Using the Wii Fit as a tool for balance assessment and neurorehabilitation: the first half decade of "Wii-search"

›
Using the Wii Fit as a tool for balance assessment and neurorehabilitation: the first half decade of "Wii-search" . Daniel J Gobl...

Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia

›
Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia . Sylvia Boesch, Wolfgang Nachbauer, Caterina Mariotti, Fr...
Sunday, February 9, 2014

Program and Abstracts for the SIMD Annual Meeting

›
Program and Abstracts for the SIMD Annual Meeting . Society for Inherited Metabolic Disorders 37th Annual Meeting; Saturday, March 9–March ...
Wednesday, February 5, 2014

The Friedreich's Ataxia Research Alliance Announces That the FDA has Granted Orphan Drug Status for Research of Untreatable Rare Disease, Friedreich's Ataxia

›
The Friedreich's Ataxia Research Alliance Announces That the FDA has Granted Orphan Drug Status for Research of Untreatable Rare Disease...
Sunday, February 2, 2014

Fellowship: NMR screening to select compounds that interact with human frataxin

›
NMR screening to select compounds that interact with human frataxin . Job details; type Fellowship, Università degli Studi di Roma Tor Ver...